GILEAD SCIENCES, INC. Deferred Compensation Arrangement with Individual, Compensation Expense
GILEAD SCIENCES, INC. (GILD) reported Deferred Compensation Arrangement with Individual, Compensation Expense of $200.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense · last filed 2026-02-24
- GILEAD SCIENCES, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2025 was $200.00M, a 1.96% decline from fiscal 2024.
- GILEAD SCIENCES, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2024 was $204.00M, a 1.92% decline from fiscal 2023.
- GILEAD SCIENCES, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2023 was $208.00M, a 18.18% increase from fiscal 2022.
- GILEAD SCIENCES, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2022 was $176.00M, a 6.02% increase from fiscal 2021.
| Period end | Deferred Compensation Arrangement with Individual, Compensation Expense 12 month | Deferred Compensation Arrangement with Individual, Compensation Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $200.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $204.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $208.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | $176.00M 10-K · filed 2025-02-28 | |
| 2021-12-31 | $166.00M 10-K · filed 2024-02-23 | |
| 2020-12-31 | $144.00M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $110.00M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $91.00M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $74.00M 10-K · filed 2020-02-25 | |
| 2016-12-31 | $69.00M 10-K · filed 2019-02-26 | |
| 2015-12-31 | $47.00M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $40.00M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $32.00M 10-K · filed 2016-02-24 | $32.40M 10-K · filed 2014-02-25 |
| 2012-12-31 | $27.00M 10-K · filed 2015-02-25 | $26.80M 10-K · filed 2013-02-27 |
| 2011-12-31 | $18.80M 10-K · filed 2014-02-25 | |
| 2010-12-31 | $11.20M 10-K · filed 2013-02-27 | |
| 2009-12-31 | $10.20M 10-K · filed 2012-02-23 | |
| 2008-12-31 | $7.80M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |